Browsing Bergen Open Research Archive by Author "Seo, Mikyung Kelly"
Now showing items 1-5 of 5
-
Cancer Biomarkers: Ethics, Economics and Society
Blanchard, Anne; Strand, Roger; Cairns, John Alexander; Tranvåg, Eirik Joakim; Norheim, Ole Frithjof; Seo, Mikyung Kelly; Wik, Elisabeth; Engen, Caroline Benedicte Nitter; Blasimme, Alessandro; Fleck, Leonard M. (Book, 2017) -
Has the development of cancer biomarkers to guide treatment improved health outcomes?
Luís, Ana Beatriz Mateus D'Avó; Seo, Mikyung Kelly (Journal article; Peer reviewed, 2021)During the last decade, testing the patient’s biomarker status prior to the administration of corresponding co-dependent therapies has been emerging in clinical practice. These biomarker-guided therapies have promoted the ... -
How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review
Seo, Mikyung Kelly; Cairns, John Alexander (Journal article; Peer reviewed, 2021)Background Despite the increasing economic assessment of biomarker-guided therapies, no clear agreement exists whether existing methods are sufficient or whether different methods might produce different cost-effectiveness ... -
HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?
Seo, Mikyung Kelly; Straume, Oddbjørn; Akslen, Lars A.; Cairns, John Alexander (Journal article; Peer reviewed, 2020)Background: Despite the extensive use of bevacizumab in a range of oncology indications, the US FDA revoked its approval for breast cancers, and multiple negative trials in several solid malignancies have been reported, ... -
A Practical Guide to Modeling and Conducting a Cost-Effectiveness Analysis of Companion Biomarker Tests for Targeted Therapies Using R: Tutorial Paper
Seo, Mikyung Kelly; Strong, Mark (Journal article; Peer reviewed, 2021)Despite the increasing number of potential biomarkers identified in laboratories and reported in much literature, the adoption of biomarkers routinely available in clinical practice to inform treatment decisions is very ...